General discussion, page-2325

Morning Chaya, I am perplexed as well but the market is full of different participants and the only good reason to sell I am thinking is actually a de-risking strategy. Not everyone is comfortable holding biotech stocks leading into human trial commencement and results from the ARDS trial.
Other than the usual pip trading suspects.

Agree as well that once the anns start coming through with the ARDS we should be sitting pretty in the mid teens (130-150M MC) preparing to submit our proposal to the FDA for EUA.

Once results come through for OSA if they are positive.. 20c will be smoked IMO. Remember that BOT traded at 250M MC last year off the back of a successful Phase 1B (Acne) Human Trial and an In Vitro preclinical study (Staph) in their bucket.

If IHL succeeds with 2 preclinicals (TBI + ARDS) and a successful Phase 2B (OSA)? Explosive upside is definitely the right term to use here.

Patience...